FOLLOWUS
1.Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing (100029), China
2.Department of Internal Medicine, Yale University School of Medicine, Connecticut (06520), USA
3.Department of Rheumatology, the Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou (310005),China
Prof. LIU Jian-ping, E-mail: liujp@bucm.edu.cn
纸质出版日期:2021-10-01,
网络出版日期:2021-07-28,
录用日期:2020-12-21
Scan for full text
Ying WANG, Mei HAN, Christopher E. Pedigo, 等. Chinese Herbal Medicine for Systemic Lupus Erythematosus:A Systematic Review and Meta-Analysis of Randomized,Placebo-Controlled Trials*[J]. Chinese Journal of Integrative Medicine, 2021,27(10):778-787.
Ying WANG, Mei HAN, Christopher E. Pedigo, et al. Chinese Herbal Medicine for Systemic Lupus Erythematosus:A Systematic Review and Meta-Analysis of Randomized,Placebo-Controlled Trials*[J]. Chinese Journal of Integrative Medicine, 2021,27(10):778-787.
Ying WANG, Mei HAN, Christopher E. Pedigo, 等. Chinese Herbal Medicine for Systemic Lupus Erythematosus:A Systematic Review and Meta-Analysis of Randomized,Placebo-Controlled Trials*[J]. Chinese Journal of Integrative Medicine, 2021,27(10):778-787. DOI: 10.1007/s11655-021-3497-0.
Ying WANG, Mei HAN, Christopher E. Pedigo, et al. Chinese Herbal Medicine for Systemic Lupus Erythematosus:A Systematic Review and Meta-Analysis of Randomized,Placebo-Controlled Trials*[J]. Chinese Journal of Integrative Medicine, 2021,27(10):778-787. DOI: 10.1007/s11655-021-3497-0.
Objective:
2
To provide evidence on the efficacy and safety of Chinese herbal medicine (CHM) as interventions for systemic lupus erythematosus (SLE).
Methods:
2
Seven electronic databases
including the Cochrane Library
Chinese National Knowledge Infrastructure (CNKI)
Chinese Scientific Journal Database (VIP)
Chinese Biomedical Literature Service System (SinoMed)
Wanfang
Embase
and PubMed
were comprehensively searched
from their inception to August 16
2020
for all randomized controlled trials (RCTs) that focused on CHM used alone or in combination with conventional medicine for SLE. Outcomes were SLE activity index (SLEDAI)
traditional Chinese medicine symptom/syndrome score (TCMSS)
dosage of glucocorticoids
main serological testing
and incidence of adverse events. Data were extracted and pooled using Review Manager 5.3 software.
Results:
2
A total of 13 RCTs enrolling 856 participants met our inclusion criteria. Meta-analyses showed that
compared to placebo
CHM had statistically significant effect on reducing SLEDAI score (MD=–1.74
95% CI: –2.29 to –1.18)
diminishing TCMSS (SMD=–0.89
95% CI: –1.16 to –0.62)
decreasing dosage of glucocorticoids (MD=–2.41 mg/d
95% CI: –3.34 to –1.48)
lowering erythrocyte sedimentation rate (MD=–4.78 mm/h
95% CI: –8.86 to –0.71)
and increasing serum complement C4 level (MD=0.03 mg/dL
95% CI: 0.00 to 0.06). No significant difference was found between CHM and placebo on adverse events.
Conclusions:
2
CHM provided significant beneficial effect on controlling disease activity and reducing dose of glucocorticoids used among SLE patients. Future advanced designed RCTs for CHM treating moderate to severe SLE with multicenter and longer follow-up are urgently needed.
Chinese herbal medicinesystemic lupus erythematoussystematic review and meta-analysisrandomized controlled trials
Rees F, Doherty M, Grainge M, Davenport G, Lanyon P,Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis 2016;75:136-141.
Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford)2017;56:i67-i77.
Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH,Izcovich A, Popoff F, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus(GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology(PANLAR). Ann Rheum Dis 2018;77:1549-1557.
Yeh KW, Yu CH, Chan PC, Horng JT, Huang JL. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. Rheumatol Int 2013;33:1805-1811.
Dorner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019;393:2344-2358.
Duarte C, Couto M, Ines L,eds. Systemic lupus erythematosus.5th ed. London: Academic Press; 2011:763-796.
Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014;384:1878-1888.
Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN,D'Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018;57:e1-e45.
Murphy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases:challenges to treatment. Lancet 2013;382:809-818.
Bell CF, Priest J, Stott-Miller M, Kan H, Amelio J, Song X, et al.Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA. Lupus Sci Med 2020;7:e000357.
Hruskova Z, Tesar V. Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. Expert Opin Biol Ther 2018;18:989-996.
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD,Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211-221.
Alvarez-Nemegyei J, Bautista-Botello A. Complementary or alternative therapy use and health status in systemic lupus erythematosus. Lupus 2009;18:159-163.
Jiao B, Gao J. Intensive research on the prospective use of complementary and alternative medicine to treat systemic lupus erythematosus. Drug Discov Ther 2013;7:167-171.
Chou CT. Alternative therapies: what role do they have in the management of lupus? Lupus 2010;19:1425-1429.
Sun J, Shao TJ, Zhang DY, ZJ X. Effect of Lang-Chuang-Ding Decoction on DNA methylation of CD70 gene promoter in peripheral blood mononuclear cells of female patients with systemic lupus erythematosus. Chin J Integr Med 2018;25:348-352.
Wang YB, Wang Q, Sheng ZY, Yao YM. Effect of Xuebijing Injection on systemic lupus erythematosus in mice. Chin J Integr Med 2013;17:105-110.
Ma YC, Lin CC, Li CI, Chiang JH, Li TC, Lin JG. Traditional Chinese medicine therapy improves the survival of systemic lupus erythematosus patients. Semin Arthritis Rheum 2016;45:596-603.
Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-1012.
Higgins JPT, Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. 2nd ed. Hoboken J:Wiley-Blackwell;2020.
Yang M, Zhang H, Liu JP. Herbal medicines for systemic lupus erythematosus. Cochrane Database of Systematic Reviews 2005; No.: CD005469. Accessed 21 June, 2021.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-640.
The State Administration of Traditional Chinses Medicine of the People's Republic of China. Guidance for clinical research of Chinese herbal medicine 2002. Beijing: China Press of Traditional Chinese Medicine; 2002:111-115.
GRADEpro GDT: GRADEpro Guideline Development Tool [Software]: McMaster University, 2015 (developed by Evidence Prime, Inc.). Accessed on Aug 16, 2020.Available at: https://gradepro.orghttps://gradepro.org.
Schünemann HBJ, Guyatt G, Oxman A,eds. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013.Accessed on Aug 16, 2020. Available at: https://gdt.gradepro.org/app/handbook/handbook.htmlhttps://gdt.gradepro.org/app/handbook/handbook.html.
Huang GH, Zhong JX, Liu Y, Chen YH, Liang XF, Duan HY, et al. Effect of Qing-yang-tou-jie mixure combined with Western medicine on vascular damage in yin-eficient SLE patients. J Tradit Chin Med (Chin) 2014;55:1029-1033.
Huang YQ, Chen JH, Wu YS, Mao YP, Fan RQ, GW X.Clinical observation of herbal medicine Lang Chuang ⅡCapsule on SLE patients and research on the relationship between sIL-2R and SLEDAI. South China J Dermato Venereol (Chin) 2007;14:337-340.
Song XW, Tang WJ, Guan TR, Dai QD, Zhang Y, Wu YJ.Treatment of severe active systemic lupus erythematosus by PMC therapy combined Langchuang Fuzheng Jiedu Capsule: a clinical observation. Chin J Integr Tradit West Med (Chin) 2013;33:1315-1319.
Wan Y, Diao QC. Clinical study of Lang Chuang Ⅱ Decoction treating systemic lupus erythematosus in remission period.Sichuan J Tradit Chin Med (Chin) 2012;30:82-83.
Dai QY, JH G. Clinical observation on Zishen Qingqi Granule combined with conventional therapy in treatment of mildly to moderately active SLE. Shanghai J Tradit Chin Med (Chin) 2019;53:65-67.
You YL, Feng YL, Cai Q, Guan JL, Zhang LL, Xu MJ, et al. Efficacy of ginsenosides combined with prednisone in patients with systemic lupus erythematosus: a prospective,randomized, double-blind, placebo-controlled trial. J Chin Integr Med (Chin) 2010;8:762-766.
Liao YN, Liu CS, Tsai TR, Hung YC, Chang SJ, Lin HL,et al. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up. Kaohsiung J Med Sci 2011;27:251-257.
Xu XF, Qu HR, Xiang ZY, Mao JC, Zhao BJ, Wang X, et al.Effects of "Ziyin Jiedu Quyu Decoction" on glucocorticoid dosage in systemic lupus erythematosus: a double-blind randomized controlled trial. Shanghai J Tradit Chin Med(Chin) 2012;46:33-36.
Zhong LL, Bian ZX, Gu JH, Zhou X, Tian Y, Mao JC,et al. Chinese herbal medicine (Zi Shen Qing) for mild-to-moderate systematic lupus erythematosus: a pilot prospective, single-blinded, randomized controlled study.Evid Based Complement Alternat Med 2013;2013:327245.
Wang YM. Evaluation of effect of Ziyin Lupus Capsule treating SLE of yin deficiency inner heat and influences made in removing of cortex hormone [Dissertation]. Guangzhou: Guangzhou University of Chinese Medicine; 2005.
Wu XX, Fan RQ, Wang Y. Seventy-six cases of systemic lupus erythematosus of yin deficiency inner heat treating by Ziyin Lupus Capsule. China J Tradit Chin Med and Pharm (Chin) 2009;24:214-216.
Shuai ZW, Xu JH, Liu S, Wei W, Xu SQ, Xu SY. Clinical study on effect of total glucosides of peony in treating systemic lupus erythematosus as adjuvant treatment. Chin J Integr Tradit West Med (Chin) 2003:188-191.
Wu FY, Sa X. The efficacy and safety of Fufang Shengdi Heji in the treatment of systemic lupus erythematosus of yin deficiency and internal heat type. Rheum Arthritis (Chin) 2017;6:27-31.
Rios-Garces R, Espinosa G, van Vollenhoven R, Cervera R.Treat-to-target in systemic lupus erythematosus: where are we? Eur J Intern Med 2020;74:29-34.
Critchley JA, Zhang Y, Suthisisang CC, Chan TY,Tomlinson B. Alternative therapies and medical science:designing clinical trials of alternative/complementary medicines—is evidence-based traditional Chinese medicine attainable? J Clin Pharmacol 2000;40:462-467.
Tonelli MR, Callahan TC. Why alternative medicine cannot be evidence-based? Acad Med 2001;76:1213-1220.
Wong W, Kuen C, Tong J, eds. Effectiveness of traditional Chinese medicine in primary care. In Kuang HX, ed. Recent advances in theories and practice of Chinese medicine. Croatia: InTech; 2012:188-208.
Liu JP, Chen KJ. Methodology guideline for clinical studies investigating traditional Chinese medicine and integrative medicine: executive summary. Complement Ther Med 2015;23:751-756.
Piantaosi S, ed. Clinical trials: a methodologic perspective.3rd ed. New York: Wiley-Interscience;2017.
Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2015;74:2006-2015.
U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Adaptive Design Clinical Trials for Drugs and Biologics—Guidance for Industry. 2019. Accessed on Aug 16, 2020. Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industryhttps://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry
Pickles T, Alten R, Boers M, Bykerk V, Christensen J,Christensen R, et al. Adaptive trial designs in rheumatology:report from the OMERACT Special Interest Group. J Rheumatol 2019;46:1406-1408.
Winthrop KL, Weinblatt ME, Bathon J, Burmester GR,Mease PJ, Crofford L, et al. Unmet need in rheumatology:reports from the targeted therapies meeting 2019. Ann Rheum Dis 2020;79:88-93.
0
浏览量
1
Downloads
1
CSCD
关联资源
相关文章
相关作者
相关机构